|
R848 VacciGrade™
The imidazoquinoline compound R848 (Resiquimod) is a guanosine derivative and an agonist for TLR7 and TLR8. This TLR7/8 agonist, originally developed as type I IFN inducer, is an effective adjuvant by activating dendritic cells (DCs) and B cells to induce cytokines optimal for Th1 cell immunity, and antibody production.
R848 VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.
Unlike other commercially available R848 preparations, InvivoGen's R848 VacciGrade™ is water soluble and controlled for TLR7/8 potency and TLR4/TLR2 contamination
R848 VacciGrade™ is for research use only, not for use in humans.
Specificity: Th1 response
Working concentration: 10 - 100 μg/mouse
Endotoxin level: <1 EU/mg
Solubility: 1 mg/ml in physiological water |